AbbVie wins FDA nod for DECNUPAZ in rare blood cancer
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
The ruling comes against the backdrop of a mounting trauma burden in India, where nearly 4.67 lakh accidental deaths occur annually
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
Libre Duo devices become the first glucose-ketone monitors approved for diabetes care, offering real-time alerts for diabetic ketoacidosis risk
Solvay will fund Pantys-led initiatives targeting vulnerable communities through product donations and menstrual health education programs
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
The syrup launched by company's Chezgreen division is designed to provide supportive care in managing common menstrual concerns such as amenorrhea, dysmenorrhea, and menorrhagia
Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
Subscribe To Our Newsletter & Stay Updated